124 related articles for article (PubMed ID: 38306385)
21. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
22. A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?
Gupta M; Karthikeyan G; Choudhury PS; Babu Koyyala VP; Sharma M; Jain P; Talwar V; Singh A; Rawal S
Cancer Invest; 2020 Sep; 38(8-9):486-492. PubMed ID: 32804008
[TBL] [Abstract][Full Text] [Related]
23.
Zang J; Liu Q; Sui H; Wang R; Jacobson O; Fan X; Zhu Z; Chen X
J Nucl Med; 2020 Dec; 61(12):1772-1778. PubMed ID: 32358086
[TBL] [Abstract][Full Text] [Related]
24. Results of a Prospective Phase 2 Pilot Trial of
Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
[TBL] [Abstract][Full Text] [Related]
25. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
[TBL] [Abstract][Full Text] [Related]
26. Preparation of
Guleria M; Amirdhanayagam J; Sarma HD; Rallapeta RP; Krishnamohan VS; Nimmagadda A; Ravi P; Patri S; Kalawat T; Das T
Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436
[TBL] [Abstract][Full Text] [Related]
27. Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.
Wang JS; Wong T; Wu KA; Mullikin TC; Armstrong A
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38395466
[TBL] [Abstract][Full Text] [Related]
28. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
29. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
30. Clinical Experience with [
Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
[TBL] [Abstract][Full Text] [Related]
31. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
Michalski K; Mix M; Meyer PT; Ruf J
Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
[TBL] [Abstract][Full Text] [Related]
32. Theranostics of Metastatic Prostate Cancer Applying
Mirzaei S; Mohammed F; Zandieh S
Curr Radiopharm; 2021; 14(4):354-358. PubMed ID: 32900357
[TBL] [Abstract][Full Text] [Related]
33. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
[TBL] [Abstract][Full Text] [Related]
34. Adoption of Lutetium-
Flegar L; Thoduka SG; Librizzi D; Luster M; Zacharis A; Heers H; Eisenmenger N; Ahmadzadehfar H; Eiber M; Weber W; Groeben C; Huber J
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2188-2195. PubMed ID: 36826478
[TBL] [Abstract][Full Text] [Related]
35. [
Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
[TBL] [Abstract][Full Text] [Related]
36. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
[TBL] [Abstract][Full Text] [Related]
37. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
38. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
39.
Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
[TBL] [Abstract][Full Text] [Related]
40. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
